Skip to main content
. 2022 May 2;21(7):1207–1218. doi: 10.1158/1535-7163.MCT-21-0840

Figure 5.

Figure 5. Bexmarilimab shows dose-dependent duration of receptor occupancy in vivo and only moderate increase in ALT levels in cynomolgus monkeys. Receptor occupancy of bexmarilimab in cynomolgus monkey monocytes after administration of a single i.v. dose of bexmarilimab at 3 mg/kg (A), 30 mg/kg (B), or 100 mg/kg (C; n  =  6 animals/dosing group). Change in MFI of CD14+ cells binding to fluorescently labeled bexmarilimab after administration of nonlabeled bexmarilimab is shown in blue and binding to fluorescently labeled 9–11 antibody is shown in orange. Concentration of the bexmarilimab in circulation (grey) was measured at the same time points as the receptor occupancy. D, Effect of bexmarilimab on ALT levels in cynomolgus monkeys on days 7 and 20 compared with predose levels. h, hours.

Bexmarilimab shows dose-dependent duration of receptor occupancy in vivo and only moderate increase in ALT levels in cynomolgus monkeys. Receptor occupancy of bexmarilimab in cynomolgus monkey monocytes after administration of a single i.v. dose of bexmarilimab at 3 mg/kg (A), 30 mg/kg (B), or 100 mg/kg (C; n  =  6 animals/dosing group). Change in MFI of CD14+ cells binding to fluorescently labeled bexmarilimab after administration of nonlabeled bexmarilimab is shown in blue and binding to fluorescently labeled 9–11 antibody is shown in orange. Concentration of the bexmarilimab in circulation (grey) was measured at the same time points as the receptor occupancy. D, Effect of bexmarilimab on ALT levels in cynomolgus monkeys on days 7 and 20 compared with predose levels. h, hours.